Article
KRAS mutation detection in Tunisian sporadic coloractal cancer patients with direct sequencing, high resolution melting and denaturating high performance liquid chromatography.
Cancer biomarkers : section A of Disease markers - 1 Jan 2010
Karim Bougatef, Florence Coulet, Kamel Rouissi, Nadia Kourda, Ines Omrane, Raja Marrakchi, Sarra Ben Jileni, Florent Soubrier, Amel Ben Ammar-Elgaaied
Abstract excerpt
The Kirsten Rat Sarcoma (KRAS) oncogene has been introduced recently as a genetic biomarker for metastatic sporadic colorectal cancer prior to anti-EGFR treatment. Identifying patients with KRAS mutations that not respond to EGFR targeted therapies require sensitive, rapid and efficacious routine technique. We have attempted to evaluate the efficiency of three conventional methods: direct sequencing, HRM and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.